macro

Deal roundup: Palo Alto, AstraZeneca, Meta and Marvell in focus

Seeking Alpha weekly roundup: Palo Alto Networks is reportedly in talks to buy a startup, while AstraZeneca offered nearly $10 billion for Rhythm.

the same feed is available to bots and dashboards through the api. connect the api →

what happened

According to Seeking Alpha, several deal reports surfaced this week. Palo Alto Networks is reportedly negotiating to buy Israeli startup Clutch Security for about $500 million, though no agreement is guaranteed. Rhythm Pharmaceuticals shares rose 22% after a report of an offer from AstraZeneca of almost $10 billion, while Edgewise Therapeutics gained 12% amid rumors that it has hired advisers for a sale.

Meta Platforms is acquiring the AI coding startup Conductor, Axios reported. Eagle Nuclear Energy signed a binding letter of intent with Noble Plains Uranium in an all-stock transaction, and MTY Group jumped 14% after Foodtastic Inc. disclosed an offer of about C$1 billion. Organigram agreed to buy Aurora Cannabis for roughly C$561 million in cash and stock, Salesforce is buying Cresta, and Marvell Technology intends to acquire Lumentum in an all-stock deal.

why it matters

For markets, roundups like this show how active merger and acquisition activity is in the technology and pharmaceutical sectors. Takeover premiums usually support the share prices of target companies, but talks may fail, so investors should weigh that uncertainty.

market impact

Target company shares: takeover reports support Rhythm and Edgewise stocks

  • Rhythm Pharmaceuticals pressure up — the reported AstraZeneca offer adds a takeover premium to the share price
  • Edgewise Therapeutics pressure up — rumors of a sales process support the share price

tags

instruments

Palo Alto NetworksRhythm PharmaceuticalsEdgewise TherapeuticsMeta PlatformsMarvell TechnologyLumentum

on polymarket

sources

  1. Key deals this week: PANW, META, OGI, CRM and more — Seeking Alpha, 7 November 2026 at 20:15 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗